Paratek Pharmaceuticals Inc (PRTK) : Birchview Capital Lp added new position in Paratek Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 11,150 shares of Paratek Pharmaceuticals Inc which is valued at $146,623 , the company said in a statement filed on Aug 9, 2016 with the SEC.Paratek Pharmaceuticals Inc makes up approximately 0.09% of Birchview Capital Lp’s portfolio.
Other Hedge Funds, Including , Teacher Retirement System Of Texas boosted its stake in PRTK in the latest quarter, The investment management firm added 199 additional shares and now holds a total of 1,602 shares of Paratek Pharmaceuticals Inc which is valued at $21,066. Turner Investments added PRTK to its portfolio by purchasing 63,480 company shares during the most recent quarter which is valued at $826,510. Paratek Pharmaceuticals Inc makes up approx 0.24% of Turner Investments’s portfolio.Swiss National Bank boosted its stake in PRTK in the latest quarter, The investment management firm added 5,500 additional shares and now holds a total of 20,900 shares of Paratek Pharmaceuticals Inc which is valued at $272,745. Wealthtrust-arizona added PRTK to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $1,292.
Paratek Pharmaceuticals Inc closed down -0.06 points or -0.46% at $12.92 with 1,23,070 shares getting traded on Wednesday. Post opening the session at $13.02, the shares hit an intraday low of $12.73 and an intraday high of $13.02 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Many Wall Street Analysts have commented on Paratek Pharmaceuticals Inc. Company shares were Reiterated by H.C. Wainwright on Jun 17, 2016 to “Buy”, Firm has raised the Price Target to $ 34 from a previous price target of $31 .Robert W. Baird Initiated Paratek Pharmaceuticals Inc on May 13, 2016 to “Outperform”, Price Target of the shares are set at $30.
Paratek Pharmaceuticals Inc. (Paratek) formerly Transcept Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI) and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily tetracycline-derived compound designed for use in the treatment of acne and rosacea.